Given that the IFGRNS scores correlated with tumour mutation burden and the tumour microenvironment, which are key factors that modulate the efficacy of ICI immunotherapy, particularly those targeting the PD‐1/PD‐L1 pathway—we speculated that IFGRNS may also serve as a predictive biomarker of response to ICI immunotherapy. Here, CD274 is linked to neoplasm.